MA34909B1 - Triterpénoïdes modifi2s en c-17 et c-3 presentant une activité inhibitrice de la maturation du vih - Google Patents
Triterpénoïdes modifi2s en c-17 et c-3 presentant une activité inhibitrice de la maturation du vihInfo
- Publication number
- MA34909B1 MA34909B1 MA36183A MA36183A MA34909B1 MA 34909 B1 MA34909 B1 MA 34909B1 MA 36183 A MA36183 A MA 36183A MA 36183 A MA36183 A MA 36183A MA 34909 B1 MA34909 B1 MA 34909B1
- Authority
- MA
- Morocco
- Prior art keywords
- triterpenoids
- modified
- inhibitory activity
- hiv maturation
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'INVENTION CONCERNE DES COMPOSÉS AYANT DES PROPRIÉTÉS MÉDICAMENTEUSES ET BIOLOGIQUES, LEURS COMPOSITIONS PHARMACEUTIQUES ET LEURS PROCÉDÉS D'UTILISATION. EN PARTICULIER, L'INVENTION CONCERNE DES TRITERPÉNOÏDES MODIFIÉS EN C-17 ET EN C-3 QUI POSSÈDENT UNE ACTIVITÉ ANTIVIRALE UNIQUE, EN TANT QU'INHIBITEURS DE MATURATION DU VIH, TEL QUE REPRÉSENTÉ PAR DES COMPOSÉS DES FORMULES I, II ET III. CES COMPOSÉS SONT UTILES POUR LE TRAITEMENT DU VIH ET DU SIDA.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161437893P | 2011-01-31 | 2011-01-31 | |
PCT/US2012/022852 WO2012106190A1 (fr) | 2011-01-31 | 2012-01-27 | Triterpénoïdes modifiés en c-17 et c-3 présentant une activité inhibitrice de la maturation du vih |
Publications (1)
Publication Number | Publication Date |
---|---|
MA34909B1 true MA34909B1 (fr) | 2014-02-01 |
Family
ID=45567147
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA36183A MA34909B1 (fr) | 2011-01-31 | 2012-01-27 | Triterpénoïdes modifi2s en c-17 et c-3 presentant une activité inhibitrice de la maturation du vih |
Country Status (24)
Country | Link |
---|---|
US (3) | US8846647B2 (fr) |
EP (1) | EP2670765B1 (fr) |
JP (1) | JP6001560B2 (fr) |
KR (1) | KR101886467B1 (fr) |
CN (1) | CN103429607B (fr) |
AR (1) | AR085053A1 (fr) |
AU (1) | AU2012212509B2 (fr) |
BR (1) | BR112013019419A2 (fr) |
CA (1) | CA2826113C (fr) |
CL (1) | CL2013002185A1 (fr) |
CO (1) | CO6751275A2 (fr) |
EA (1) | EA022470B1 (fr) |
ES (1) | ES2653847T3 (fr) |
IL (1) | IL227678B (fr) |
MA (1) | MA34909B1 (fr) |
MY (1) | MY162186A (fr) |
PE (1) | PE20141152A1 (fr) |
PT (1) | PT2670765T (fr) |
SG (1) | SG192144A1 (fr) |
TN (1) | TN2013000321A1 (fr) |
TW (1) | TWI628188B (fr) |
UY (1) | UY33886A (fr) |
WO (1) | WO2012106190A1 (fr) |
ZA (1) | ZA201306546B (fr) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102066397B (zh) | 2008-04-18 | 2013-09-11 | 里亚塔医药公司 | 包含抗炎症药效团的化合物以及使用方法 |
US7915402B2 (en) | 2008-04-18 | 2011-03-29 | Reata Pharmaceuticals, Inc. | Antioxidant inflammation modulators: oleanolic acid derivatives with saturation in the C-ring |
WO2009129548A1 (fr) | 2008-04-18 | 2009-10-22 | Reata Pharmaceuticals, Inc. | Modulateurs d’inflammation antioxydants : dérivés d’acide oléanolique homologués c-17 |
AU2009237579C1 (en) | 2008-04-18 | 2016-05-12 | Reata Pharmaceuticals Holdings, LLC | Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17 |
EA025568B1 (ru) | 2010-12-17 | 2017-01-30 | Рита Фармасьютикалз, Инк. | Пиразолильные и пиримидинильные трициклические еноны в качестве антиоксидантных модуляторов воспаления |
DK2670764T3 (en) * | 2011-01-31 | 2015-12-07 | Bristol Myers Squibb Co | C-28 AMINES OF MODIFIED C-3-BETULIN ACID DERIVATIVES AS ANTI-HUMIDITY INHIBITORS |
EA026847B1 (ru) | 2011-03-11 | 2017-05-31 | Рита Фармасьютикалз, Инк. | C4-монометилтритерпеноидные производные и способы их применения |
AU2012312485B2 (en) | 2011-09-21 | 2016-09-01 | VIIV Healthcare UK (No.5) Limited | Novel betulinic acid derivatives with antiviral activity |
US8906889B2 (en) * | 2012-02-15 | 2014-12-09 | Bristol-Myers Squibb Company | C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity |
PE20150160A1 (es) | 2012-04-27 | 2015-02-19 | Reata Pharmaceuticals Inc | Derivados de 2,2-difluoropropionamida de bardoxolona metilo, formas polimorficas y metodos de uso de los mismos |
US8889854B2 (en) | 2012-05-07 | 2014-11-18 | Bristol-Myers Squibb Company | C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity |
WO2013188818A1 (fr) | 2012-06-15 | 2013-12-19 | Reata Pharmaceuticals, Inc. | Modulateurs anti-inflammation basés sur des triterpénoïdes époxydés au niveau du cycle a et leurs méthodes d'utilisation |
JP6389174B2 (ja) * | 2012-08-15 | 2018-09-12 | グラクソ グループ リミテッドGlaxo Group Limited | 化学的方法 |
US9278912B2 (en) | 2012-09-10 | 2016-03-08 | Reata Pharmaceuticals, Inc. | C13-hydroxy derivatives of oleanolic acid and methods of use thereof |
UY35023A (es) | 2012-09-10 | 2014-03-31 | Reata Pharmaceuticals Inc | Derivados c17-alcandiilo y alquendiilo del ácido oleanólico y sus métodos de uso |
US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
EP2953960A1 (fr) * | 2013-02-06 | 2015-12-16 | Bristol-Myers Squibb Company | Triterpénoïdes modifiés en c-19 ayant une activité inhibant la maturation du vih |
KR20150121712A (ko) * | 2013-02-25 | 2015-10-29 | 브리스톨-마이어스 스큅 컴퍼니 | Hiv의 치료에 유용한 c-3 알킬 및 알케닐 개질된 베툴린산 유도체 |
MA39374A1 (fr) | 2014-04-11 | 2018-06-29 | Viiv Healthcare Uk No 4 Ltd | Triterpénoïdes présentant une activité d'inhibition de la maturation du vih, substitués en 3ème position par un cycle non aromatique portant un substituant halogénoalkyle |
US9920090B2 (en) | 2014-06-19 | 2018-03-20 | VIIV Healthcare UK (No.5) Limited | Betulinic acid derivatives with HIV maturation inhibitory activity |
EP3218387A1 (fr) | 2014-11-14 | 2017-09-20 | VIIV Healthcare UK (No.5) Limited | Dérivés d'oxolupène |
RU2017118576A (ru) | 2014-11-14 | 2018-12-14 | ВАЙВ ХЕЛТКЕР ЮКей (N5) ЛИМИТЕД | C-17-арил-замещённые аналоги бетулиновой кислоты |
US10221208B2 (en) | 2015-04-14 | 2019-03-05 | ViiV Healthcare UK (No.4) Limited | Methods of producing an HIV maturation inhibitor |
JP2018521107A (ja) | 2015-07-28 | 2018-08-02 | グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited | Hiv感染を予防または治療するためのベツイン誘導体 |
WO2017017609A1 (fr) | 2015-07-28 | 2017-02-02 | Glaxosmithkline Intellectual Property (No.2) Limited | Dérivés de bétuine permettant de ou de traiter des infections à vih |
WO2017025901A1 (fr) * | 2015-08-11 | 2017-02-16 | Hetero Research Foundation | Nouveaux analogues de c28 à modifications en c3 de dérivés triterpéniques à utiliser en tant qu'inhibiteurs du vih |
CA2998681C (fr) | 2015-09-23 | 2024-02-06 | Reata Pharmaceuticals, Inc. | Derives d'acide oleanolique modifie en c4 pour l'inhibition de l'il-17 et d'autres utilisations |
KR20180054826A (ko) | 2015-09-24 | 2018-05-24 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | Hiv 성숙 억제 활성을 갖는 화합물 |
CA3004856A1 (fr) | 2015-11-20 | 2017-05-26 | Albert J. Delmonte | Formulations d'inhibiteurs de maturation du vih |
WO2017125870A1 (fr) | 2016-01-20 | 2017-07-27 | Glaxosmithkline Intellectual Property (No.2) Limited | Dérivés amine de lupanes ayant une activité inhibitrice de la maturation du vih |
AR107512A1 (es) | 2016-02-04 | 2018-05-09 | VIIV HEALTHCARE UK Nº 5 LTD | Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1 |
EP3478703A1 (fr) * | 2016-06-30 | 2019-05-08 | ViiV Healthcare UK (No.5) Limited | Inhibiteurs triterpénoïdes de la réplication du virus de l'immunodéficience humaine |
WO2018044822A1 (fr) * | 2016-08-31 | 2018-03-08 | Viiv Healthcare Company | Combinaisons, utilisations et traitements correspondants |
WO2019060051A1 (fr) | 2017-08-04 | 2019-03-28 | Ardelyx, Inc. | Dérivés d'acide glycyrrhétinique de traitement de l'hyperkaliémie |
JP6926939B2 (ja) * | 2017-10-23 | 2021-08-25 | 東京エレクトロン株式会社 | 半導体装置の製造方法 |
JP6977474B2 (ja) * | 2017-10-23 | 2021-12-08 | 東京エレクトロン株式会社 | 半導体装置の製造方法 |
JP7436385B2 (ja) | 2018-04-24 | 2024-02-21 | ヴィーブ ヘルスケア ユーケー(ナンバー5)リミテッド | Hiv成熟阻害活性を有する化合物 |
PL237998B1 (pl) | 2018-05-28 | 2021-06-28 | Narodowy Inst Lekow | Fosfonowe pochodne kwasu 3-karboksyacylobetulinowego, sposób ich otrzymywania oraz ich zastosowanie |
WO2020163642A1 (fr) | 2019-02-07 | 2020-08-13 | Ardelyx, Inc. | Dérivés d'acide glycyrrhétinique destinés à être utilisés dans le traitement de l'hyperkaliémie |
US20220177439A1 (en) | 2019-02-11 | 2022-06-09 | Hetero Labs Limited | Novel triterpene derivatives as hiv inhibitors |
GB2598300A (en) * | 2020-08-21 | 2022-03-02 | Univ Durham | Cross-linking method and applications in bioconjugation |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5413999A (en) | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
US5962527A (en) | 1995-03-21 | 1999-10-05 | The Board Of Trustees Of The University Of Illinois | Method and composition for treating cancers |
US5869535A (en) | 1995-03-21 | 1999-02-09 | The Board Of Trustees Of The University Of Illinois | Method and composition for selectively inhibiting melanoma |
US5679828A (en) | 1995-06-05 | 1997-10-21 | Biotech Research Labs, Inc. | Betulinic acid and dihydrobetulinic acid derivatives and uses therefor |
US20020137755A1 (en) | 2000-12-04 | 2002-09-26 | Bilodeau Mark T. | Tyrosine kinase inhibitors |
US20040110785A1 (en) | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
US7365221B2 (en) | 2002-09-26 | 2008-04-29 | Panacos Pharmaceuticals, Inc. | Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof |
US20050014730A1 (en) | 2003-04-02 | 2005-01-20 | Carlson Robert M. | Anti-fungal formulation of triterpene and essential oil |
US7745625B2 (en) | 2004-03-15 | 2010-06-29 | Bristol-Myers Squibb Company | Prodrugs of piperazine and substituted piperidine antiviral agents |
US20050239748A1 (en) | 2004-03-17 | 2005-10-27 | Panacos Pharmaceuticals, Inc. | Pharmaceutical salts of 3-O-(3',3'-dimethylsuccinyl) betulinic acid |
TW200628161A (en) | 2004-11-12 | 2006-08-16 | Panacos Pharmaceuticals Inc | Novel betulin derivatives, preparation thereof and use thereof |
US8067620B2 (en) | 2005-05-04 | 2011-11-29 | Medicines For Malaria Venture Mmv | Dispiro 1,2,4-trioxolane antimalarials |
WO2008127364A2 (fr) * | 2006-10-13 | 2008-10-23 | Myriad Genetics, Inc. | Composés antiviraux et utilisation de ceux-ci |
US20110144069A1 (en) | 2006-10-16 | 2011-06-16 | Myriad Genetics, Incorporated | Compounds for treating viral infections |
CA2714049A1 (fr) * | 2008-02-14 | 2009-08-20 | Virochem Pharma Inc. | Nouveaux derives de 17ss-lupane |
US9067966B2 (en) * | 2009-07-14 | 2015-06-30 | Hetero Research Foundation, Hetero Drugs Ltd. | Lupeol-type triterpene derivatives as antivirals |
WO2011153315A1 (fr) * | 2010-06-04 | 2011-12-08 | Bristol-Myers Squibb Company | Dérivés d'acide bétulinique modifiés en c-3, utilisés comme inhibiteurs de maturation du vih |
EP2576586B1 (fr) * | 2010-06-04 | 2015-08-12 | Bristol-Myers Squibb Company | Amides c-28 de dérivés d'acide bétulinique modifiés en c-3, utilisés comme inhibiteurs de maturation du vih |
-
2012
- 2012-01-27 BR BR112013019419A patent/BR112013019419A2/pt not_active Application Discontinuation
- 2012-01-27 AU AU2012212509A patent/AU2012212509B2/en active Active
- 2012-01-27 WO PCT/US2012/022852 patent/WO2012106190A1/fr active Application Filing
- 2012-01-27 PT PT127029478T patent/PT2670765T/pt unknown
- 2012-01-27 EP EP12702947.8A patent/EP2670765B1/fr active Active
- 2012-01-27 CN CN201280014966.XA patent/CN103429607B/zh active Active
- 2012-01-27 KR KR1020137023070A patent/KR101886467B1/ko active IP Right Grant
- 2012-01-27 ES ES12702947.8T patent/ES2653847T3/es active Active
- 2012-01-27 MY MYPI2013701325A patent/MY162186A/en unknown
- 2012-01-27 JP JP2013551362A patent/JP6001560B2/ja active Active
- 2012-01-27 CA CA2826113A patent/CA2826113C/fr active Active
- 2012-01-27 PE PE2013001719A patent/PE20141152A1/es active IP Right Grant
- 2012-01-27 MA MA36183A patent/MA34909B1/fr unknown
- 2012-01-27 EA EA201391127A patent/EA022470B1/ru not_active IP Right Cessation
- 2012-01-27 SG SG2013056858A patent/SG192144A1/en unknown
- 2012-01-27 US US13/359,727 patent/US8846647B2/en active Active
- 2012-01-31 TW TW101103140A patent/TWI628188B/zh active
- 2012-01-31 AR ARP120100314A patent/AR085053A1/es unknown
- 2012-01-31 UY UY0001033886A patent/UY33886A/es not_active Application Discontinuation
-
2013
- 2013-07-26 TN TNP2013000321A patent/TN2013000321A1/fr unknown
- 2013-07-28 IL IL227678A patent/IL227678B/en active IP Right Grant
- 2013-07-30 CL CL2013002185A patent/CL2013002185A1/es unknown
- 2013-08-27 CO CO13203030A patent/CO6751275A2/es unknown
- 2013-08-30 ZA ZA2013/06546A patent/ZA201306546B/en unknown
-
2014
- 2014-07-24 US US14/339,572 patent/US20140343000A1/en not_active Abandoned
-
2016
- 2016-02-04 US US15/015,741 patent/US20160151387A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA34909B1 (fr) | Triterpénoïdes modifi2s en c-17 et c-3 presentant une activité inhibitrice de la maturation du vih | |
MA41013A (fr) | Compositions comprenant des souches bactériennes | |
MX2022009942A (es) | Composiciones farmaceuticas que comprenden epa y un agente cardiovascular y metodos para utilizar el mismo. | |
MA39211B1 (fr) | Composés tricycliques comme agents anti-cancers | |
MA53399B1 (fr) | Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine | |
MA40225B1 (fr) | Composés dihydroisoquinolinone substitués | |
MA37712B1 (fr) | Inhibiteurs macrocycliques de virus flaviviridae | |
PH12017500841A1 (en) | 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors | |
MA41185B1 (fr) | Composés d'acide isoxazole hydroxamique comme inhibiteurs de lpxc | |
EA201491531A1 (ru) | C-3 циклоалкенил тритерпеноиды, ингибирующие созревание вич | |
MA31117B1 (fr) | Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes | |
MX2013011691A (es) | Inhibidores de la replicacion viral, su proceso de preparacion y sus usos terapeuticos. | |
MA35638B1 (fr) | 2-thiopyrimidinones | |
MA39170B1 (fr) | Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer | |
MA39374A1 (fr) | Triterpénoïdes présentant une activité d'inhibition de la maturation du vih, substitués en 3ème position par un cycle non aromatique portant un substituant halogénoalkyle | |
MA40886B1 (fr) | Nouveau triterpénone en c-3 avec des dérivés d'amide inverse en c-28 en tant qu'inhibiteurs du vih | |
MA38190A2 (fr) | Inhibiteurs d'autotaxine | |
MA43052B1 (fr) | Inhibiteurs de la kallicréine plasmatique humaine | |
MA35281B1 (fr) | Dosage et administration d'anticorps anti-erbb3 en combinaison avec le paclitaxel pour le traitement de cancers gynécologiques | |
MA38253B1 (fr) | Compositions comprenant de la vortioxétine et du donépézil | |
MA43960A (fr) | Triterpénoïdes modifiés en c-3 et c-17 utilisés comme inhibiteurs du vih-1 | |
MA38678A1 (fr) | Dérivés nucléosidiques 4'-azido, 3'désoxy-3'-fluoro substitués | |
MA38009A1 (fr) | Composes d'azaindoline substitues qui ont une activite inhibitrice de la proteine d'apoptose pour leurs utilisations dans le traitement et/ou la prophylaxie du cancer | |
MA39719B1 (fr) | Pyrazoles substitués par un trifluoromethyle en tant qu`inhibiteurs de la kallicréine plasmatique humaine | |
MA45367B1 (fr) | Inhibiteurs de la tyrosine kinase |